Gilead inks deal for cancer-beating antibody

18-10-2022

Catherine Wycherley

Gilead inks deal for cancer-beating antibody

Sundry Photography / Shutterstock.com

Gilead will have an exclusive licence and will pay MacroGenics $60 million upfront | Deal includes tiered, double-digit royalties on worldwide net sales.


Gilead, MacroGenics, CD123, blood cancers, licensing, royalties, big pharma

LSIPR